The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2025 | Optimizing post-CAR T-cell monitoring in lymphoma: evidence with the use of liso-cel
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, discusses research exploring how to optimize post-CAR T-cell monitoring in patients receiving lisocabtagene maraleucel (liso-cel), commenting on the potential to shorten the mandated four-week requirement for patients to stay within a certain radius of the treating academic center after receiving CAR-T therapy. Dr Kamdar highlights that the majority of adverse events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), occur within the first 15 days after infusion, suggesting that a shorter monitoring period may be sufficient. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
